Form 4: Trevi Therapeutics Director Edward T. Mathers Acquires Stock Options

Director Edward T. Mathers acquired 30,000 nonstatutory stock options in Trevi Therapeutics, Inc. on June 13, 2024.

Summary

• On June 13, 2024, Edward T. Mathers, a director of Trevi Therapeutics, Inc., acquired 30,000 nonstatutory stock options.
• The exercise price of these options is $2.77.
• The options vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, contingent upon continued service.
• The options expire on June 12, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service, suggesting an expectation of ongoing involvement by the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates